We had so many informative presentations at our 2018 Screening and Care Conference that we wanted to make sure everyone has access to this information. Check out top presentations on molecular testing and targeted therapy, improving access to care, the importance of a multidisciplinary conference for screening, and patient tracking software. They’re all on our new YouTube playlist: For Professionals.
The LCA Science and Research team just returned from the 2019 Targeted Therapies of Lung Cancer Meeting, and we have good news: treatment options continue to expand in the targeted therapies and immunotherapy space to treat all types of lung cancer. Here’s what we learned. All of the advancements presented emphasize the importance of molecular testing/biomarker testing so that the best treatments can be chosen for a patient’s unique cancer. There are currently approved targeted therapies for patients whose cancers [...]
Last year was an exciting year for lung cancer research with more U.S. Food and Drug Administration (FDA) approval decisions relevant to lung cancer than ever before. So, what can we expect for 2019? Another eventful year with researchers studying how to best give the approved drugs (i.e. what order and combinations) as well as expanding the options with more types of therapies. IMMUNOTHERAPY IN NON-SMALL CELL LUNG CANCER First, there is the rapidly growing field of immunotherapy. We have [...]
Tuesday, November 27, 2018 - The U.S. Food and Drug Administration (FDA) granted accelerated approval to larotrectinib (VITRAKVI, Loxo Oncology Inc. and Bayer) for adult and pediatric patients with advanced solid tumors, including lung cancer, that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known resistance mutation. These gene fusions can be in the NTRK1, NTRK2, or NTRK3 genes. Patients with advanced lung cancer who had NTRK gene fusions were included in the research that led to this [...]
Thursday, April 19, 2018 – This week the Food and Drug Administration (FDA) approved targeted therapy drug, osimertinib (Tagrisso), as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors with the EGFR mutations. The approval is based off results from a study showing that Tagrisso as a first-line treatment prevented the cancer from progressing for 8.7 months longer than erlotinib (Tarceva) and gefitinib (Iressa). Up until this point, Tagrisso was approved as a second-line treatment [...]